摘要
目的探讨阿帕替尼治疗化疗失败晚期非小细胞肺癌患者的临床效果。方法选择2016年3月至2018年3月136例化疗失败晚期非小细胞肺癌患者,随机分为两组各68例,对照组接受二线化疗方案,研究组在对照组基础上加用阿帕替尼治疗。两组患者每6周评价一次无进展生存期,末次随访时检测血清细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)水平,评价临床疗效。结果研究组血清CYFRA21-1为(3.47±1.02)ng/mL、CEA为(12.33±2.47)ng/mL、VEGF为(10.55±1.73)ng/L,均优于对照组,P<0.05。研究组的有效率及临床获益率均明显高于对照组,P<0.05。研究组的中位无进展生存期为4.29个月(0.80~7.00)个月;对照组的中位无进展生存期为3.17个月(0.50~6.20)个月,研究组的中位无进展生存期明显长于对照组,比较具有统计学意义(P<0.05)。结论晚期非小细胞肺癌患者一线化疗失败后可首选阿帕替尼治疗,临床效果好,可明显延长无进展生存期。
Objective To investigate the clinical effect of apatinib in the treatment of patients with advanced non-small cell lung cancer that failed chemotherapy.Methods From March 2016 to March 2018,136 patients with advanced non-small cell lung cancer who had failed chemotherapy were randomly divided into two groups,with 68 cases in each group.The control group received second-line chemotherapy,and the study group was added with apatinib on the basis of the control group.The two groups of patients were evaluated for progression-free survival every 6 weeks.Serum levels of cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA)and vascular endothelial growth factor(VEGF)were detected at the last follow-up to evaluate the clinical efficacy.Results The study group’s serum CYFRA21-1 was(3.47±1.02)ng/mL,CEA was(12.33±2.47)ng/mL,and VEGF was(10.55±1.73)ng/L,all of which were better than the control group,P<0.05.The effective rate and clinical benefit rate of the study group were significantly higher than those of the control group,P<0.05.The median progression-free survival in the study group was 4.29 months(0.80-7.00)months;the median progression-free survival in the control group was 3.17 months(0.50-6.20)months,and the median progression-free survival in the study group obviously longer than the control group,the comparison is statistically significant(P<0.05).Conclusion After the failure of first-line chemotherapy in patients with advanced non-small cell lung cancer,apatinib can be the first choice for treatment,which has good curative effect and can significantly prolong progressionfree survival.
作者
陈爱香
CHEN Aixiang(Department of Radiation Oncology,Dandong First Hospital,Dandong 118000,China)
出处
《中国医药指南》
2021年第13期34-35,共2页
Guide of China Medicine
关键词
晚期非小细胞肺癌
阿帕替尼
化疗失败
临床效果
Advanced non-small cell lung cancer
Apatinib
Failed chemotherapy
Clinical effect
